Search Results

The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of potentially fatal brain swelling and bleeding.

Coya Therapeutics, Inc. announces that the Alzheimer’s Drug Discovery Foundation (“ADDF”) has purchased 603,136 shares of the Company’s common stock at a purchase price of $8.29 per share for an aggregate investment of $5 million.

Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had pledged to share the results whether “good, bad or ambiguous.”

After years of controversy and allegations of doctored data, Cassava is moving on from Alzheimer’s.

The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its Alzheimer’s disease drug simufilam.

Harrington Discovery Institute Center for Brain Health Medicines at University Hospitals and the Alzheimer’s Drug Discovery Foundation announce a joint request for proposals for the 2024 ADDF-Harrington Scholar Award.

Filippo Berio, one of the nation’s top-selling and longstanding olive oil brands, has established an exclusive partnership with the Alzheimer’s Drug Discovery Foundation to raise awareness for Alzheimer’s disease and contribute crucial funds to support groundbreaking research aimed at finding a cure for Alzheimer’s and related dementias.

Brain diagnostics innovator BrainScope announced today a new investment from the Alzheimer’s Drug Discovery Foundation (ADDF) in BrainScope’s current Series B equity financing round.